In this regard, ADCs used in breast cancer treatment include Kadcyla and Enhertu, targeting human epidermal growth factor receptor 2 (HER2) [2], and Trodelvy, targeting trophoblast cell surface antigen-2 (TROP2) [3]. Here, TACSTD2 is linked to breast cancer.